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Ursolic acidUrsolic acid (3b-hydroxy-urs-12-en-28-oic acid) is a natural pentacyclic triterpenoid that is present
in many plants, including medicinal herbs, and foods. Ursolic acid was initially identiﬁed as an
inhibitor of the expression of intercellular adhesion molecule-1 (ICAM-1) in response to interleu-
kin-1a (IL-1a). We report here a novel biological activity: ursolic acid inhibits intracellular trafﬁck-
ing of proteins. Ursolic acid markedly inhibited the IL-1a-induced cell-surface ICAM-1 expression in
human cancer cell lines and human umbilical vein endothelial cells. By contrast, ursolic acid exerted
weak inhibitory effects on the IL-1a-induced ICAM-1 expression at the protein level. Surprisingly, we
found that ursolic acid decreased the apparent molecular weight of ICAM-1 and altered the struc-
tures of N-linked oligosaccharides bound to ICAM-1. Ursolic acid induced the accumulation of
ICAM-1 in the endoplasmic reticulum, which was linked mainly to high-mannose-type glycans.
Moreover, in ursolic-acid-treated cells, the Golgi apparatus was fragmented into pieces and distrib-
uted over the cells. Thus, our results reveal that ursolic acid inhibits intracellular trafﬁcking of pro-
teins and induces the accumulation of ICAM-1 linked to high-mannose-type glycans in the
endoplasmic reticulum.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Pro-inﬂammatory cytokines, such as interleukin-1 (IL-1), induce
the expression of a variety of genes essential for inﬂammatory re-
sponses, including intercellular adhesion molecule-1 (ICAM-1;
CD54) [1,2]. ICAM-1 is a transmembrane glycoprotein consisting
of 505 amino acids and possesses multiple N-linked glycosylation
sites [3,4]. ICAM-1 interacts with b2 integrins LFA-1 (CD11a/
CD18) and Mac-1 (CD11b/CD18) expressed on the surface of leuko-
cytes [5,6]. Upon stimulation with pro-inﬂammatory cytokines,
vascular endothelial cells are induced to express cell-surface
ICAM-1, which mediates the interaction with circulatingleukocytes and is necessary for their tissue inﬁltration [7]. The le-
vel of ICAM-1 expression on the cell-surface is mainly regulated at
the step of transcription. The transcription factor nuclear factor jB
(NF-jB) plays a major role in the induction of ICAM-1 expression
[8,9].
Pro-inﬂammatory cytokines, such as IL-1, induce the NF-jB sig-
naling pathway, which is involved in not only inﬂammatory dis-
ease, but also cancer and metabolic disease [10,11]. The inhibitor
of NF-jB (IjB) family of proteins forms a complex with the NF-
jB heterodimer in the cytosol [12,13]. In response to IL-1a or IL-
1b, IL-1 receptor mainly induces the activation of IjB kinase that
phosphorylates IjB at the N-terminal serine residues, and phos-
phorylated IjB is immediately ubiquitinated and hydrolyzed by
the proteasome [14,15]. The NF-jB heterodimer becomes free
and translocates to the nucleus where it promotes the transcrip-
tion of many target genes by binding to their jB sites [16]. It has
been reported that various types of small molecules inhibit the
NF-jB signaling pathway and the NF-jB-dependent gene expres-
sion [17,18].
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tacyclic triterpenoid carboxylic acid, is found as amajor constituent
in many plants, including medicinal herbs and edible plants. It has
been shown that ursolic acid exerts a wide range of biological activ-
ities, including anti-inﬂammatory activity [19,20]. We previously
isolated ursane-, oleanane-, lupane-, and taraxasterane-type triter-
penes from Nerium oleander and our structure–activity relationship
study revealed that ursolic acid inhibits the expression of cell-sur-
face ICAM-1 most effectively among these triterpenes [21,22]. In
relation to these ﬁndings, it has been shown that ursolic acid blocks
the NF-jB-dependent signaling pathway and its downstream gene
expression [23–30]. In this study, we investigated the inhibitory
mechanism of ursolic acid on the IL-1a-induced cell-surface ICAM-
1 expression in human cancer cell lines and human normal cells.
In contrast to previous reports, our results revealed thenovel biolog-
ical activity of ursolic acid targeting the intracellular trafﬁcking of
proteins.
2. Materials and methods
2.1. Cells
Human lung carcinoma A549 cells (JCRB0076) were provided by
National Institute of Biomedical Innovation JCRB Cell Bank (Osaka,
Japan). A549 cells and human breast adenocarcinoma MCF-7 cells
were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% heat-inactivated fetal calf serum
(Nichirei Biosciences, Tokyo, Japan) and penicillin–streptomycin
mixed solution (Nacalai Tesque, Kyoto, Japan). HUVEC were ob-
tained from Lonza (Walkersville, MD, USA). HUVEC were main-
tained in EGM™-2 BulletKit™ (2% FBS) according to the
manufacturer’s protocol.
2.2. Reagents
Ursolic acid was purchased from Sigma–Aldrich (St. Louis, MO,
USA). Castanospermine, concanamycin A, and tunicamycin were
obtained from Wako Pure Chemical Industries (Osaka, Japan).
(+)-Brefeldin A (Merck Millipore, Darmstadt, Germany), 1-deoxym-
annojirimycin hydrochloride (Enzo Life Sciences, Plymouth Meet-
ing, PA, USA; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1-
deoxynojirimycin hydrochloride (Cayman Chemical, Ann Arbor,
MI, USA), MG-132 (Peptide Institute, Osaka, Japan) and swainso-
nine (Cayman) were commercially obtained.
2.3. Antibodies
Antibodies to b-actin (AC-15; Sigma–Aldrich), calnexin
(EPR3632; Epitomics, Burlingame, CA, USA), E-selectin (H-300;
Santa Cruz Biotechnology), glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (6C5; Santa Cruz Biotechnology), Golgi matrix
protein (GM130) (EP892Y; Epitomics), ICAM-1 (clone 15.2; Leinco
Technologies, St. Louis, MO, USA), ICAM-1 (Clone 28; BD Biosci-
ences, San Diego, CA, USA), NF-jB p50 (H-119; Santa Cruz Biotech-
nology), NF-jB p65 (C-20; Santa Cruz Biotechnology), poly(ADP-
ribose) polymerase (PARP) (C-2–10; Sigma–Aldrich) and VCAM-1
(H-276; Santa Cruz) were commercially obtained.
2.4. Cell-ELISA assay
Cells were washed twice with phosphate-buffered saline (PBS)
and ﬁxed with PBS containing 1% paraformaldehyde for 15 min.
The ﬁxed cells were washed twice with PBS and blocked with
PBS containing 1% bovine serum albumin (BSA) overnight. The cells
were treated with anti-ICAM-1 antibody (clone 15.2) in 1% BSA–PBS for 60 min and washed three times with 0.02% Tween 20–
PBS. Then, the cells were incubated with horseradish peroxidase
(HRP)-conjugated antibody (Jackson ImmunoResearch, West
Grove, PA, USA) in 1% BSA–PBS for 60 min and washed three times
with 0.02% Tween 20–PBS. HRP activity was determined by incuba-
tion with 200 mM sodium citrate (pH 5.3) containing o-phenylene-
diamine dihydrochloride and 0.02% H2O2 until a yellow color
developed. Absorbance at 415 nm was measured with a Model
680 microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).
The IL-1a-stimulated cells without test samples and no cells were
used for positive control and background, respectively. ICAM-1
expression (%) was calculated by the following formula: (test sam-
ples – background)/(positive control – background)  100.
2.5. Assay for cell viability
Cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) at the ﬁnal concentration of
500 lg/ml for 2 h. The cells were solubilized with 5% sodium dode-
cyl sulfate overnight. Absorbance at 595 nm was measured with
the Model 680 microplate reader.
2.6. Western blotting
Cells were washed once with PBS and lysed with Triton X-100
lysis buffer (50 mM Tris–HCl (pH 7.4), 1% Triton X-100, 2 mM
dithiothreitol, 2 mM sodium orthovanadate) containing the prote-
ase inhibitor cocktail Complete™ (Roche Diagnostics, Mannheim,
Germany). Cell lysates as cytoplasmic fractions were collected as
supernatants by centrifugation (15,300g, 5 min). Precipitates were
washed twice with Triton X-100 lysis buffer, and then solubilized
as nuclear fractions. Proteins (30 lg/lane) were separated by
SDS–polyacrylamide gel electrophoresis and transferred onto Hy-
bond-ECL nitrocellulose membranes (GE Healthcare, Piscataway,
NJ, USA). The membranes were blocked with 4% skim milk in
0.5% Tween 20–PBS, and then reacted with primary antibodies
and HRP-conjugated secondary antibodies (Jackson ImmunoRe-
search). Protein bands were developed with Western blotting
detection reagent (GE Healthcare) and detected by exposure to
Hyperﬁlm™ ECL (GE Healthcare) or ImageQuant LAS 4000 mini
(GE Healthcare).
2.7. Assay for glycosidase digestion
Peptide: N-glycosidase F (PNGase F) and endoglycosidase H
(Endo H) were obtained from New England Biolabs (Ipswich, MA,
USA). Cell lysates were prepared as described above. Cell lysates
(20 lg protein) were heated at 100 C for 10 min and then incu-
bated with or without PNGase F (250 units) or Endo H (250 units)
at 37 C for 60 min according to the manufacturers’ protocols. Pro-
teins were separated by SDS–polyacrylamide gel electrophoresis
and analyzed by Western blotting.
2.8. Fluorescent microscopy
Coverslips were treated with Cellmatrix Type I-C (Nitta Gela-
tin, Osaka, Japan) for collagen coating. Cells were cultured on the
collagen-coated coverslips overnight prior to experiments. For
ﬁxation, the cells were treated with 4% paraformaldehyde–PBS
for 15 min, washed three times with PBS, and then washed twice
with 25 mM glycine–PBS. The cells were treated with cold meth-
anol and washed three times with 0.3% Triton X-100–PBS for per-
meabilization. The ﬁxed cells were blocked with 5% BSA–PBS
overnight. The cells were stained serially with 5% BSA–PBS con-
taining rabbit anti-GM130 antibody, rabbit anti-calnexin anti-
body, or mouse anti-ICAM-1 antibody for primary antibodies
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or Alexa-488-conjugated anti-mouse IgG antibody (Invitrogen)
for secondary antibodies for 1 h. Then, the cells were washed
three times with 0.3% Triton X-100–PBS between antigen–anti-
body reactions. The coverslips were mounted on glass slides with
FluorSave™ (Merck Millipore). The stained cells were observed
with a confocal laser scanning microscope system FV10i (Olym-
pus, Tokyo, Japan). To quantify the morphological changes of
the Golgi apparatus, cells were stained with rabbit anti-GM130
antibody and Alexa-594-conjugated anti-rabbit IgG antibody.
The shapes of the Golgi apparatus were classiﬁed into a normal
type (gathered in a small area), a disrupted type (fragmented
and scattered over the cells) and other ambiguous types. The
number of cells that harbored these particular types of the Golgi
apparatus was counted over multiple ﬁelds under a ﬂuorescence
light microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany) until
the total cell number was more than a hundred cells.Fig. 1. Ursolic acid inhibits IL-1a-induced cell-surface ICAM-1 expression. (A–C) A5
concentrations of ursolic acid for 1 h and then incubated with (ﬁlled circles) or with
measured by the Cell-ELISA assay. ICAM-1 expression (%) is represented by the means ± S.
at least three independent experiments. (D–F) A549 cells (D), MCF-7 cells (E), and HUVE
incubated with (ﬁlled circles) or without (open circles) IL-1a (0.25 ng/ml) for 6 h. Cell
means ± S.D. of triplicate cultures. ⁄P < 0.05 and ⁄⁄P < 0.01, compared with control. Data2.9. Assay for a-mannosidase activity
a-Mannosidase from Canavalia ensiformis (Jack bean) (29 units/
mg) and 4-nitrophenyl-a-D-mannopyranoside were obtained from
Sigma–Aldrich and Tokyo Chemical Industry (Tokyo, Japan),
respectively. Jack bean a-mannosidase (0.05 unit) was incubated
with 50 mM sodium phosphate buffer (pH 6.8) containing 2 mM
4-nitrophenyl-a-D-mannopyranoside at 37 C for 15 min. Absor-
bance at 405 nm was measured with the Model 680 microplate
reader.
2.10. Statistical analysis
Statistical signiﬁcance was assessed by one-way ANOVA fol-
lowed by the Tukey test for multiple comparisons. Differences of
P < 0.05 were considered to be statistically signiﬁcant.49 cells (A), MCF-7 cells (B), and HUVEC (C) were preincubated with various
out (open circles) IL-1a (0.25 ng/ml) for 6 h. Cell-surface ICAM-1 expression was
D. of triplicate cultures. ⁄⁄P < 0.01, compared with control. Data are representative of
C (F) were preincubated with various concentrations of ursolic acid for 1 h and then
viability (%) was measured by the MTT assay. Cell viability is represented by the
are representative of three independent experiments.
Fig. 2. Ursolic acid does not inhibit IL-1a-induced expression of ICAM-1 at the
protein level but affects its post-translational modiﬁcation. A549 cells (A), MCF-7
cells (B), and HUVEC (C) were preincubated with various concentrations of ursolic
acid for 1 h and then incubated with IL-1a (0.25 ng/ml) for 6 h. Cell lysates were
analyzed by Western blotting. Data are representative of at least three independent
experiments for A549 cells and MCF-7 cells and two independent experiments for
HUVEC.
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3.1. Ursolic acid inhibits IL-1a-induced cell-surface ICAM-1 expression
Human lung carcinoma A549 cells and human breast adenocar-
cinomaMCF-7 cells were induced to express ICAM-1 in response to
IL-1a stimulation [31,32]. A549 cells and MCF-7 cells were prein-
cubated with ursolic acid for 1 h and then incubated with IL-1a
for 6 h. Then, the amount of cell-surface ICAM-1 was quantitated
by the Cell-ELISA assay. Ursolic acid inhibited the IL-1a-induced
cell-surface ICAM-1 expression in A549 cells in a dose-dependent
manner and almost completely at concentrations higher than
30 lM (Fig. 1A). The IL-1a-induced cell-surface ICAM-1 expression
in MCF-7 cells was also inhibited by ursolic acid (Fig. 1B). In addi-
tion to those cell lines, HUVEC were induced to express cell-surface
ICAM-1 in response to IL-1a. Ursolic acid at concentrations higher
than 30 lM inhibited the IL-1a-induced cell-surface ICAM-1
expression in HUVEC (Fig. 1C). In A549 cells and MCF-7 cells, urso-
lic acid did not affect cell viability even at concentrations as high as
50 lM (Fig. 1D and E). In HUVEC, ursolic acid decreased cell viabil-
ity partially at concentrations that inhibited ICAM-1 expression
(Fig. 1F). However, it seems that ursolic acid can exert cytotoxic ef-
fects over longer time periods, since ursolic acid decreased cell via-
bility during 24 h incubation in A549 cells (Fig. S1). Together, these
data indicate that ursolic acid inhibits the expression of cell-sur-
face ICAM-1 induced by IL-1a in human cancer cells and normal
cells.
3.2. Ursolic acid affects IL-1a-induced ICAM-1 post-translational
modiﬁcation
We next investigated the effect of ursolic acid on the NF-jB sig-
naling pathway induced by IL-1 receptor. Ursolic acid slightly aug-
mented the IL-1a-induced translocation of NF-jB subunits, p65
and p50, from the cytoplasm to the nucleus in A549 cells
(Fig. S2). These data suggested that ursolic acid inhibits cell-surface
ICAM-1 expression at the steps downstream of NF-jB activation.
We therefore examine the effect of ursolic acid on ICAM-1 expres-
sion at the protein level by Western blotting. ICAM-1 was detected
as multiple bands migrating to more than 80 kDa in A549 cells
stimulated with IL-1a (Fig. 2A). Unexpectedly, we found that urso-
lic acid weakly affected the total amount of ICAM-1 but decreased
the molecular weight of ICAM-1 to 60–70 kDa in A549 cells
(Fig. 2A). In MCF-7 cells and normal human umbilical vein endo-
thelial cells (HUVEC), ursolic acid also decreased the molecular
weight of ICAM-1 to values similar to those observed in A549 cells
(Fig. 2B and C). In addition, ursolic acid decreased the molecular
weights of E-selectin and VCAM-1 in HUVEC (Fig. 2C). These results
indicate that ursolic acid marginally reduces the IL-1a-induced
protein synthesis of ICAM-1 but affects the post-translational mod-
iﬁcation of ICAM-1.
3.3. Ursolic acid affects N-linked oligosaccharide processing of ICAM-1
ICAM-1 is a transmembrane glycoprotein consisting of 505 ami-
no acids and possesses multiple consensus sites for N-linked glyco-
sylation [3,4]. Tunicamycin is known to block the synthesis of N-
linked oligosaccharides on glycoproteins [33]. Consistent with a
previous report [34], an unglycosylated form of ICAM-1 was de-
tected as bands migrating to around 50–55 kDa in tunicamycin-
treated cells (Fig. 3A). Indeed, the size of ICAM-1 in the tunicamy-
cin-treated cells was apparently smaller than that in the ursolic-
acid-treated cells (Figs. 2A, 3A). Moreover, tunicamycin at concen-
trations higher than 1 lM decreased the cell-surface ICAM-1
expression in A549 cells (Fig. 3B). By contrast, tunicamycin didnot affect cell viability at concentrations up to 10 lM during 6 h
incubation (Fig. 3C).
Glycoproteins undergo N-linked oligosaccharide processing
during intracellular trafﬁcking. Cell lysates were subjected to PNG-
ase F or Endo H digestion and Western blot analysis. ICAM-1 was
converted by PNGase F into an unglycosylated form migrating at
50–55 kDa (Fig. 3D). Endo H was unable to digest ICAM-1 in un-
treated A549 cells (Fig. 3D). By contrast, Endo H was able to digest
the oligosaccharide chains of ICAM-1 in ursolic-acid-treated A549
cells (Fig. 3D). Thus, these data indicate that high-mannose-type
glycans are mainly linked to ICAM-1 in ursolic-acid-treated cells.
3.4. Ursolic acid induces accumulation of ICAM-1 in endoplasmic
reticulum (ER)
The subcellular localization of ICAM-1 was further analyzed by
confocal microscopy (Figs. S3 and S4 for lower magniﬁcation
images, and Fig. 4A and B for higher magniﬁcation images of rep-
Fig. 3. Ursolic acid affects N-linked oligosaccharide processing of ICAM-1. (A) A549 cells were treated with various concentrations of tunicamycin for 1 h and then incubated
with (+) or without () IL-1a (0.25 ng/ml) for 6 h. Cell lysates were analyzed by Western blotting. Data are representative of three independent experiments. (B) A549 cells
were preincubated with various concentrations of tunicamycin for 1 h and then incubated with (ﬁlled circles) or without (open circles) IL-1a (0.25 ng/ml) for 6 h. Cell-surface
ICAM-1 expression was measured by the Cell-ELISA assay. ICAM-1 expression (%) is represented by the means ± S.D. of triplicate cultures. ⁄⁄P < 0.01, compared with control.
Data are representative of four independent experiments. (C) A549 cells were preincubated with various concentrations of tunicamycin for 1 h and then incubated with (ﬁlled
circles) or without (open circles) IL-1a (0.25 ng/ml) for 6 h. Cell viability (%) was measured by the MTT assay. Cell viability (%) is represented by the means ± S.D. of triplicate
cultures. Data are representative of three independent experiments. (D) A549 cells were preincubated with (+) or without () ursolic acid (50 lM) for 1 h and then incubated
with (+) IL-1a (0.25 ng/ml) for 6 h. Cell lysates were treated or not treated with PNGase F or Endo H, and analyzed by Western blotting. Data are representative of three
independent experiments.
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apparatus and the ER, respectively [35,36]. Control A549 cells did
not express ICAM-1, whereas IL-1a stimulation induced the
expression of ICAM-1 over the whole cell including the cell periph-
ery (Fig. 4A and B). Only a part of ICAM-1 was co-localized with
GM130 and calnexin in IL-1a-stimulated cells (Fig. 4A and B). This
staining pattern suggests that a large part of ICAM-1 is transported
from the Golgi apparatus and present on the cell surface. When
A549 cells were preincubated with ursolic acid and then incubated
with IL-1a, ICAM-1 was accumulated around the nucleus and co-
localized markedly with calnexin but barely with GM130 (Fig. 4A
and B). Thus, these results indicate that ursolic acid induces the
accumulation of ICAM-1 in the ER. In addition, we observed that
the Golgi apparatus is fragmented and scattered over the cells
upon exposure to ursolic acid regardless of the presence or absence
of IL-1a (Fig. 4A). To quantify the morphological changes of the
Golgi apparatus, the shapes of the Golgi apparatus were classiﬁed
into a normal type, a disrupted type and other types by using ﬂuo-
rescent microscopy. Ursolic acid signiﬁcantly decreased the per-
centage of cells harboring the normal Golgi apparatus, and
conversely increased the percentage of cells harboring the dis-
rupted Golgi apparatus (Fig. 5A and B).
3.5. Ursolic acid attenuates N-linked oligosaccharide processing of
ICAM-1 at steps similar to 1-deoxymannojirimycin
A number of alkaloid-type compounds are known to inhibit N-
linked glycoprotein processing [37]. Brefeldin A induces the disas-sembly and redistribution of the Golgi apparatus and inhibits pro-
tein transport [38,39]. To gain an insight into the mode of action of
ursolic acid, we further investigated the effects of these inhibitors
on ICAM-1 expression. 1-Deoxynojirimycin (an inhibitor ofa-gluco-
sidase I) at concentrations of up to 100 lM did not obviously affect
the molecular weight of ICAM-1, whereas castanospermine (also
an inhibitor of a-glucosidase I), swainsonine (an inhibitor of Golgi
a1,2-mannosidase II), and concanamycin A (an inhibitor of vacuolar
type H+-ATPase) decreased the molecular weight of ICAM-1 to a va-
lue between those of control cells and ursolic-acid-treated cells
(Fig. 6A). By contrast, brefeldin A (an inhibitor of protein transport)
at the concentration of 100 nM decreased the molecular weight of
ICAM-1 to avalue similar to that observed in theursolic-acid-treated
cells (Fig. 6AandB). In addition tobrefeldinA, 1-deoxymannojirimy-
cin (an inhibitor ofGolgia1,2-mannosidase I) at the concentrationof
100 lMdecreased themolecularweight of ICAM-1 to a value similar
to that observed with ursolic acid (Fig. 6A and C).
Cell lysates prepared from brefeldin-A- or 1-deoxymannojiri-
mycin-treated A549 cells were digested with PNGase F or Endo H
and analyzed by Western blotting. In the brefeldin-A-treated
A549 cells, Endo H did not digest ICAM-1 to sizes similar to that
observed by PNGase F digestion (Fig. 6D), indicating that ICAM-1
contains both high-mannose-type and other-type oligosaccharide
chains in a single polypeptide. In the 1-deoxymannojirimycin-trea-
ted cells, ICAM-1 was sensitive to Endo H, and most of ICAM-1 was
digested by Endo H into multiple fragments whose molecular
weights were similar to or slightly higher than those of fragments
obtained by PNGase F digestion (Fig. 6D).
Fig. 4. Ursolic acid induces accumulation of ICAM-1 in ER. A549 cells were preincubated with or without ursolic acid (50 lM) for 1 h and then incubated with or without IL-
1a (0.25 ng/ml) for 6 h in the presence or absence of ursolic acid. Cells were ﬁxed and stained for ICAM-1 (green), together with GM130 (red) (A) and calnexin (red) (B) as
markers of Golgi apparatus and ER, respectively. Panels A and B show higher magniﬁcation images of representative cells in Figs. S3 and S4, respectively. Scale bars represent
20 lm. Data are representative of at least three independent experiments. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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Fig. 5. Ursolic acid induces morphological changes of Golgi apparatus. A549 cells
were incubated in the presence or absence of ursolic acid (50 lM) for 6 h. Cells were
stained for GM130 (red), and the shapes of the Golgi apparatus were observed
under a ﬂuorescence light microscope (A). Scale bars represent 20 lm. The number
of cells harboring a normal type, a disrupted type, and other types of the Golgi
apparatus was measured (B). Cell number (%) is represented by the means ± S.D. of
three independent experiments. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Ursolic acid attenuates N-linked oligosaccharide processing in a manner
similar to brefeldin A or 1-deoxymannojirimycin. (A–C) A549 cells were preincu-
bated with or without ursolic acid (50 lM), tunicamycin (1 lM), concanamycin A
(10 lM), castanospermine (300 lM), 1-deoxynojirimycin (100 lM), brefeldin A
(100 nM), 1-deoxymannojirimycin (100 lM) or swainsonine (100 nM) for 1 h and
incubated with (+) or without () IL-1a (0.25 ng/ml) for 6 h in the presence or
absence of the compounds (A). A549 cells were preincubated with various
concentrations of brefeldin A (B) or 1-deoxymannojirimycin (C) for 1 h and
incubated with (+) or without () IL-1a (0.25 ng/ml) for 6 h. Cell lysates were
analyzed by Western blotting. Data are representative of at least two independent
experiments. (D) A549 cells were preincubated with or without ursolic acid
(50 lM), brefeldin A (100 nM) or 1-deoxymannojirimycin (100 lM) for 1 h and then
incubated with IL-1a (0.25 ng/ml) for 6 h. Cell lysates were treated (+) or not
treated with () PNGase F or Endo H and analyzed by Western blotting. Data are
representative of three independent experiments.
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apparatus in a manner distinct from brefeldin A
The IL-1a-induced cell-surface ICAM-1 expression was reduced
to less than 20% by 1-deoxynojirimycin (up to 100 lM), castano-
spermine (up to 300 lM), and swainsonine (up to 1 lM) in A549
cells (data not shown). Moreover, 1-deoxymannojirimycin at con-
centrations up to 100 lM did not inhibit the IL-1a-induced cell-
surface ICAM-1 expression (Fig. 7A). By contrast, brefeldin A at
concentrations higher than 100 nM inhibited the IL-1a-induced
cell-surface ICAM-1 expression almost completely (Fig. 7B). Thus,
it seems that ICAM-1 can be efﬁciently transported to the cell sur-
face without trimming by a-glucosidases or a-mannosidases.
Ursolic acid barely affected the activity of Jack bean a-mannosi-
dase (Fig. 8A), whereas 1-deoxymannojirimycin inhibited the en-
zyme activity (Fig. 8B).
The intracellular localization of ICAM-1 in A549 cells exposed to
brefeldin A or 1-deoxymannojirimycin was further analyzed by
confocal microscopy (Figs. S5 and S6 for lower magniﬁcation
images, and Fig. 9A and B for higher magniﬁcation images of rep-
resentative cells). Brefeldin A, but not 1-deoxymannojirimycin,
was found to induce the fragmentation of the Golgi apparatus
(Fig. 9A). Brefeldin A induced the accumulation of ICAM-1 primar-
ily in the ER, as a large part of ICAM-1 was localized at the periph-
ery of the nucleus and co-localized with calnexin in the brefeldin-
A-treated A549 cells (Fig. 9B). However, in contrast to the ursolic-
acid-treated cells, ICAM-1 was also merged with GM130 to some
extent in the brefeldin-A-treated cells (Fig. 9A). By contrast, the
localization of ICAM-1 in the 1-deoxymannojirimycin-treated cells
was similar to that in control cells, as ICAM-1 was dispersed over
the whole cell and a part of ICAM-1 was co-localized with both
GM130 and calnexin (Fig. 9A and B). This is consistent with theobservation that 1-deoxymannojirimycin did not inhibit cell-sur-
face ICAM-1expression (Fig. 7A).
4. Discussion
Ursolic acid has been reported to possess multiple biological
activities [19,20]. We previously reported that ursolic acid inhibits
cell-surface ICAM-1 expression in response to inﬂammatory cyto-
kines [21,29]. In line with those reports, ursolic acid has been re-
ported to inhibit the constitutive expression of ICAM-1 in cancer
cell lines and the TNF-a-induced ICAM-1 expression in HUVEC
[40–43]. Moreover, we found that ursolic acid reduces the
Fig. 7. Brefeldin A, but not 1-deoxymannojirimycin, inhibits IL-1a-induced cell-
surface ICAM-1 expression. A549 cells were preincubated with various concentra-
tions of 1-deoxymannojirimycin (A) or brefeldin A (B) for 1 h and then incubated
with IL-1a (0.25 ng/ml) for 6 h. Cell-surface ICAM-1 expression was measured by
the Cell-ELISA assay. ICAM-1 expression (%) is represented by the means ± S.D. of
triplicate cultures. ⁄⁄P < 0.01, compared with control. Data are representative of at
least three independent experiments.
Fig. 8. Ursolic acid does not inhibit a-mannosidase activity. Jack bean a-mannos-
idase was preincubated with various concentrations of ursolic acid (A) or 1-
deoxymannojirimycin (B) for 30 min and then incubated with 4-nitrophenyl-a-D-
mannopyranoside for 15 min. a-Mannosidase activity (%) is represented by the
means ± S.D. of three independent experiments.
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ATPase and amino acid transport [29]. In contrast to those reports
[29], ursolic acid exerted weak inhibitory effects on ICAM-1
expression at the protein level but profoundly inhibited cell-sur-
face ICAM-1 expression in response to IL-1a stimulation in human
cancer cell lines and normal cells. Therefore, we investigated the
molecular mechanism by which ursolic acid inhibits cell-surface
ICAM-1 expression. In this study, we discovered the novel biolog-
ical activity of ursolic acid targeting the intracellular trafﬁcking
of proteins.
Ursolic acid inhibited the intracellular transport of glycopro-
teins from the ER to the Golgi apparatus. This may be ascribed to
the dysfunction of the Golgi apparatus as ursolic acid induced
the fragmentation of the Golgi apparatus. Brefeldin A is known to
cause the disassembly of the Golgi apparatus and its redistribution
to the ER [38,39]. In a manner similar to ursolic acid, the Golgi
apparatus was fragmented into pieces and dispersed in brefeldin-
A-treated cells. Nevertheless, ICAM-1 present in ursolic-acid-trea-
ted cells was very sensitive to Endo H, whereas ICAM-1 present
in brefeldin-A-treated cells was partially resistant to Endo H. This
may be due to that oligosaccharide-processing enzymes localized
in the Golgi apparatus are translocated into the ER by promotion
of retrograde transport and those enzymes can further modify
the oligosaccharide chains in brefeldin-A-treated cells. It has been
reported that ursolic acid exerts some inhibitory activity on yeast
a-glucosidase [44,45]. However, speciﬁc inhibitors of a-glucosi-
dases or a-mannosidases exerted only weak effects on the trans-
port of ICAM-1 to the cell surface. Thus, these results suggest
that ursolic acid directly targets the Golgi apparatus and thereby
inhibits the intracellular trafﬁcking of glycoproteins in a mecha-
nism distinct from brefeldin A.
ICAM-1 possesses multiple N-linked glycosylation sites [3,4]. It
has been reported that soluble ICAM-1 comprising of heavily-gly-
cosylated N-terminal two immunoglobulin superfamily domains
are mostly insensitive to Endo H when expressed in HEK293T cells
[4]. Consistent with this, a large part of ICAM-1 in IL-1a-stimulated
A549 cells was resistant to Endo H. By contrast, ICAM-1 present in
ursolic-acid-treated cells became sensitive to Endo H. In addition,
the molecular weight of ICAM-1 in the ursolic-acid-treated cells
was similar to that in the 1-deoxymannojirimycin- or brefeldin-
A-treated cells. We also found that ursolic acid induces the accu-
mulation of ICAM-1 in the ER. Thus, it is most likely that the N-
linked glycans of ICAM-1 in ursolic-acid-treated cells are high-
mannose types prior to the digestion with Golgi a1,2-mannosidase
I.
It has been recently reported that TNF-a stimulation induces
the production of two distinct ICAM-1 bands in HUVEC: a major
band at 95 kDa and a minor band at 75 kDa, which was linked
to high-mannose-type glycans, and that high-mannose-type
ICAM-1 is functionally distinct from fully-glycosylated ICAM-1
[46]. We observed that IL-1a induces the expression of ICAM-1
bands migrating to more than 80 kDa as major forms and those
migrating to 60–70 kDa as minor forms in HUVEC. The minor
ICAM-1 forms might be linked to high-mannose-type glycans,
since their sizes were similar to those found in ursolic-acid-treated
HUVEC. These results suggest that IL-1a itself promotes the
expression of high-mannose-type ICAM-1 in a manner similar to
TNF-a at least in HUVEC. However, in A549 cells, the expression
of high-mannose-type ICAM-1 was barely induced by IL-1a alone.
In contrast to ursolic acid that blocked the cell-surface ICAM-1
expression, 1-deoxymannojirimycin promoted the cell-surface
expression of high-mannose-type ICAM-1 in IL-1a-stimulated
A549 cells. Therefore, the inhibition of Golgi a1,2-mannosidase I
might be one of critical steps to promote the cell-surface expres-
sion of high-mannose-type ICAM-1.
Fig. 9. Ursolic acid inhibits intracellular protein transport from ER to Golgi apparatus in a manner distinct from brefeldin A. A549 cells were preincubated with or without
ursolic acid (50 lM), brefeldin A (100 nM) or 1-deoxymannojirimycin (100 lM) for 1 h and then incubated with IL-1a (0.25 ng/ml) for 6 h in the presence or absence of the
compounds. Cells were ﬁxed and stained for ICAM-1 (green), together with GM130 (red) (A) and calnexin (red) (B) as markers of Golgi apparatus and ER, respectively. Panels A
and B show higher magniﬁcation images of representative cells in Figs. S5 and S6, respectively. Scale bars represent 20 lm. Data are representative of at least three
independent experiments. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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pathway activated constitutively or in response to pro-inﬂamma-
tory cytokines or chemotherapeutic agents [30]. Consistent with
those reports, we previously showed that ursolic acid reduces the
amount of TNF-a-induced ICAM-1 mRNA by 40–50% in A549 cells
[29]. Thus, this biological activity of ursolic acid contributes, at
least in part, to the inhibition of the TNF-a-induced ICAM-1
expression at the protein level. In contrast to TNF-a, however,
ursolic acid slightly augmented the IL-1a-induced NF-jB activa-
tion in A549 cells, and did not obviously decrease the IL-1a-in-
duced ICAM-1 expression at the protein level in human cancer
cells. By contrast, it has been reported that the IL-1b-induced NF-
jB signaling pathway is inhibited by ursolic acid in rat C6 glioma
cells [26]. Thus, it seems that ursolic acid blocks the IL-1-induced
NF-jB signaling pathway in a cell-type-speciﬁc manner.
We previously showed that speciﬁc inhibitors of Na+/K+-ATPase
(e.g. ouabain) block Na+-dependent amino acid transport and
thereby inhibits the NF-jB-responsive gene expression induced
by TNF-a or IL-1a [47]. Ouabain did not affect the TNF-a-induced
ICAM-1 mRNA expression but strongly inhibited ICAM-1 expres-
sion at the protein level [46]. We and other groups reported that
ursolic acid inhibits the activity of puriﬁed Na+/K+-ATPase
[29,48,49]. In a mechanism similar to ouabain, ursolic acid is likely
to inhibit amino acid transport and de novo protein synthesis via
the inhibition of Na+/K+-ATPase. However, in contrast to ouabain,
ursolic acid not only decreased the TNF-a-induced expression of
ICAM-1 at the protein level but also reduced the molecular weight
of ICAM-1 [29]. As ouabain at any concentrations did not alter the
molecular weight of ICAM-1 but solely inhibited ICAM-1 expres-
sion [47], the inhibition of Na+/K+-ATPase activity may not be
responsible for the blockage of ICAM-1 transport to the cell surface
in ursolic-acid-treated cells.
Cell-surface molecules, such as ICAM-1, are induced in response
to inﬂammatory cytokines and play an essential role in inﬂamma-
tion [7]. Ursolic acid is a constituent of many plants, including
medicinal herbs, and foods [19,20]. Thus, ursolic acid might be ex-
pected to a potential natural product that exhibits anti-inﬂamma-
tory activity in vivo. To date, the pharmacokinetic studies of ursolic
acid in humans and animal models have been reported [43,50–54].
The oral administration of the herb Sambucus chinensis L. (known
as Lu-Ying) extract at a dose containing ursolic acid (80.32 mg/
kg) caused the maximum concentration of 294.8 ng/ml (calculated
to be 0.645 lM) in the rat plasma [50]. In mice fed orally with
ursolic acid (250 mg/kg) and ursolic acid-enriched diet (1%, w/w),
the serum concentrations of ursolic acid were reported to be
480 ng/ml (1.05 lM) and 600–1300 ng/ml (1.31–2.85 lM), respec-
tively [43,51]. In humans, the oral administration of ursolic acid
(32 mg) led to the concentration of 27.95 ± 14.20 ng/ml
(0.061 ± 0.031 lM) [52]. Moreover, two recent studies have re-
ported that the concentrations of ursolic acid are
3404.6 ± 748.8 ng/ml (7.45 ± 1.64 lM) and 1835–3457 ng/ml
(4.02–7.57 lM) after the intravenous injection of ursolic acid in
humans [53,54]. These studies suggest that the concentrations of
ursolic acid are in the physiological range of 7.5 lM in humans.
Our dose-dependent experiments have shown that ursolic acid
effectively inhibits intracellular trafﬁcking of proteins at 20–
30 lM in three human cancer and normal cell lines. Thus, it seems
that the physiological concentrations of ursolic acid in vivo are at
least 4-fold lower than the concentrations reported here. The effec-
tive concentrations of ursolic acid might be optimized by in vitro
experiments, which screen particular cell types more sensitive to
ursolic acid and extend preincubation times with ursolic acid. Fur-
thermore, in vivo experiments to explore the effect of ursolic acid
on ICAM-1 expression and intracellular trafﬁcking of proteins are
necessary for the development of ursolic acid as an anti-inﬂamma-
tory agent.In conclusion, we found that ursolic acid affects the morphology
of the Golgi apparatus and inhibits the intracellular trafﬁcking of
proteins from the ER to the Golgi apparatus. However, the biolog-
ical activity of ursolic acid on the glycoprotein transport is distinct
from that of brefeldin A. In this regard, ursolic acid may be a useful
bioprobe for investigating the molecular mechanism underlying
the intracellular trafﬁcking of proteins and the morphology of
the Golgi apparatus.
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